Condition: Unresectable Hepatocellular Carcinoma · Sponsor: West China Hospital
This clinical trial was designed to evaluate the safety and efficacy of Y90-SIRT combined with nivolumab, ipilimumab, and lenvatinib in patients with unresectable HCC. In addition to assessing short-term efficacy endpoints, such as ORR and PFS, this trial places particular emphasis on the OS benefit for patients. This study is therefore both novel and innovative.
This description comes directly from the study's public registry record.
Chang Liu, 医生 · +86 189 8060 6382 · drliuchang@wchscu.cn
Ruihong Dai, 医生 · 18715779637 · 760173632@qq.com
Always discuss trial participation with your own doctor first.
| Study Chair Liu Chang , West China Hospital | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07482059